390 related articles for article (PubMed ID: 24083677)
1. Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy.
Constantine GD; Bruyniks N; Princic N; Huse D; Palmer L; Lenhart G; Blumentals WA; Nappi RE
Curr Med Res Opin; 2014 Jan; 30(1):143-8. PubMed ID: 24083677
[TBL] [Abstract][Full Text] [Related]
2. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe.
DiBonaventura M; Luo X; Moffatt M; Bushmakin AG; Kumar M; Bobula J
J Womens Health (Larchmt); 2015 Sep; 24(9):713-22. PubMed ID: 26199981
[TBL] [Abstract][Full Text] [Related]
3. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study.
Nappi RE; Seracchioli R; Salvatore S; Cagnacci A; Di Paolantonio T; Busacca M;
Gynecol Endocrinol; 2019 May; 35(5):453-459. PubMed ID: 30700188
[TBL] [Abstract][Full Text] [Related]
4. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Pinkerton JV; Stanczyk FZ
Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
[TBL] [Abstract][Full Text] [Related]
5. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause.
Palacios S; Nappi RE; Bruyniks N; Particco M; Panay N;
Climacteric; 2018 Jun; 21(3):286-291. PubMed ID: 29553288
[TBL] [Abstract][Full Text] [Related]
6. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.
Nappi RE; Palacios S; Panay N; Particco M; Krychman ML
Climacteric; 2016 Apr; 19(2):188-97. PubMed ID: 26581580
[TBL] [Abstract][Full Text] [Related]
7. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
8. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
Vicariotto F; Raichi M
Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
[TBL] [Abstract][Full Text] [Related]
9. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.
Pinkerton JV; Bushmakin AG; Komm BS; Abraham L
Maturitas; 2017 Jun; 100():57-63. PubMed ID: 28539177
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
11. Macro-regional variation in attitudes toward and experiences of vulvar and vaginal atrophy among Italian post-menopausal women: a post hoc analysis of REVIVE survey data.
Nappi RE; Particco M; Biglia N; Cagnacci A; Di Carlo C; Luisi S; Paoletti AM
Gynecol Endocrinol; 2017 May; 33(5):389-394. PubMed ID: 28277131
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
13. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study.
Palma F; Volpe A; Villa P; Cagnacci A;
Maturitas; 2016 Jan; 83():40-4. PubMed ID: 26421474
[TBL] [Abstract][Full Text] [Related]
14. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.
Kingsberg SA; Larkin L; Krychman M; Parish SJ; Bernick B; Mirkin S
Menopause; 2019 Feb; 26(2):124-131. PubMed ID: 30130293
[TBL] [Abstract][Full Text] [Related]
15. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S
Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
[TBL] [Abstract][Full Text] [Related]
16. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety.
Vicariotto F; DE Seta F; Faoro V; Raichi M
Minerva Ginecol; 2017 Aug; 69(4):342-349. PubMed ID: 28608667
[TBL] [Abstract][Full Text] [Related]
17. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
Nappi RE; Palacios S
Climacteric; 2014 Feb; 17(1):3-9. PubMed ID: 24423885
[TBL] [Abstract][Full Text] [Related]
18. The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate.
Krychman M; Graham S; Bernick B; Mirkin S; Kingsberg SA
J Sex Med; 2017 Mar; 14(3):425-433. PubMed ID: 28202319
[TBL] [Abstract][Full Text] [Related]
19. Pelvic floor muscles training to reduce symptoms and signs of vulvovaginal atrophy: a case study.
Mercier J; Morin M; Lemieux MC; Reichetzer B; Khalifé S; Dumoulin C
Menopause; 2016 Jul; 23(7):816-20. PubMed ID: 27219835
[TBL] [Abstract][Full Text] [Related]
20. The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study.
Nappi RE; Di Carlo C; Becorpi AM; Gambacciani M; De Seta F; Ribaldone R; Benedetto C; Paoletti AM;
J Obstet Gynaecol; 2020 May; 40(4):512-519. PubMed ID: 31496326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]